about
Antimicrobial Doses in Continuous Renal Replacement Therapy: A Comparison of Dosing Strategies.Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients.Etanercept clearance during an in vitro model of continuous venovenous hemofiltration.Drug-associated renal dysfunction.Drug dosing considerations in alternative hemodialysis.Amino Acid requirements in critically ill patients with acute kidney injury treated with continuous renal replacement therapy.Reenvisioning assessment for the Academy and the Accreditation Council for Pharmacy Education's standards revision process.Optimizing anemia management in hospitalized patients with end-stage renal disease.Drug dosing during continuous renal replacement therapy.Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.Antibiotic pharmacokinetic and pharmacodynamic considerations in patients with kidney disease.Antibiotic dosing in critically ill patients with acute kidney injury.Principles and operational parameters to optimize poison removal with extracorporeal treatments.Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much".Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis.Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View.We Underdose Antibiotics in Patients on CRRT.Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer.Vancomycin assay performance in patients with acute renal failure.Pharmacokinetics of intravenously administered levofloxacin in men and women.Modeled dalbavancin transmembrane clearance during intermittent and continuous renal replacement therapies.In vitro glucose kinetics during continuous renal replacement therapy: implications for caloric balance in critically ill patients.Ethambutol optic neuropathy in a hemodialysis patient receiving a guideline-recommended dose.Linezolid clearance during continuous venovenous hemodiafiltration: a case report.Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin.Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose.Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).Medication dosing in critically ill patients with acute kidney injury treated with renal replacement therapy.In vitro clearance of trace elements via continuous renal replacement therapy.Enhanced clearance of highly protein-bound drugs by albumin-supplemented dialysate during modeled continuous hemodialysis.Subcutaneous terbutaline use in CKD to reduce potassium concentrations.Quantification of creatinine kinetic parameters in patients with acute renal failure.Transplacental passage of vancomycin in noninfected term pregnant women.Tedizolid Adsorption and Transmembrane Clearance during in vitro Continuous Renal Replacement Therapy.Antibiotic dosing in critically ill patients receiving CRRT: underdosing is overprevalent.Pharmacist leads primary care team to improve diabetes care.Effects of peridialytic oral supplements on nutritional status and quality of life in chronic hemodialysis patients.Survey of pharmacists’ antibiotic dosing recommendations for sustained low-efficiency dialysis.
P50
Q27313917-05DFDF24-981E-461D-B626-06D7BFF14FB1Q33518268-EBA4177A-4240-46CA-8271-8BA82FF64195Q34038286-43D85A74-0A7D-4F2D-8E32-0F7EFC5A02C4Q36469777-B11C680F-6A87-4771-8D75-4F82099E4DEDQ36866256-9D04F887-47DF-4192-BC37-79C0B3CACE41Q37151322-342B202D-68A5-476A-9C98-7A5B5CE1446FQ37181950-85103E8C-2921-4DDE-85BD-B8D096BA9C8CQ37367706-F952F30A-10CB-491D-856A-62A508642683Q37475122-E21990D3-16FF-4D55-BD56-8C68B8EF1CACQ37643628-4BD6BA6C-61F7-46C9-8050-B96DE51A890DQ37781451-BFB9E05F-3BDC-4CA6-AA7E-DCE0333B5A01Q37846092-2E9351E6-8EED-43EF-BD75-F039F6799CDEQ38211484-A49450CE-49E8-4DF6-8A23-C282CDD18392Q38261172-CFE4F58A-169E-4DE3-BDF7-FAB21C3A55FCQ38499259-A40066A1-F6FA-432F-A266-25A36289CAF0Q38693212-7083DA27-D5B6-4982-9F87-644A9DA7559AQ38809129-9B2B878C-E759-4604-B64F-C16CEC7FCA34Q39965478-7A9885F2-277A-413F-B683-1A8FFF365476Q41385538-B8236919-4D0A-46BD-99DE-8E6412911EDBQ42605189-E0888522-C48A-44B7-8886-78C170E64D30Q42618044-6FCA2D50-1F5E-42AC-BBC1-BB43A362AD87Q42668977-3DBA09F4-951B-45F4-9465-F65DE7BE644FQ43001453-0032B8DD-0090-4EC5-B74D-2A105EA90798Q44115813-9EEF9CA8-790B-4616-B64E-A12E980F7E37Q44141019-AFD03AD5-558A-460C-A992-47513166A990Q44551308-D5382CE7-E660-4833-8B18-F649CDE75F79Q44679646-8C813D74-6E55-4107-A1DF-53EF2E39E941Q44761716-390C1D19-8920-4AA7-B544-E350506541FEQ44969186-A404A453-E973-4AD8-ADA4-D2D0CE032036Q45901585-1B0ADFC8-4602-4DC1-9479-61FE281CBA8EQ45949422-850FD919-D6EA-4A70-AD98-EF1A797ABAF8Q46413726-7E7B8502-00BE-4D5E-9934-888CA6819AE9Q46547784-26DA4EDF-1AFD-4413-90EC-FF8CCA0A2DC1Q47742074-252E1CB8-BA29-4148-B7BB-EC47D82CE4B5Q50696412-B3408CE3-40D7-4DC4-8D6A-2C0B24C91A7FQ50895636-A5E23B19-DA94-4E4C-9606-C994CFEC4817Q51040518-0A1CAF56-7F52-49B7-BD2C-B8C1802B3F5FQ51759318-C582F33B-B44B-414F-973B-45CFF4DA3FD9Q51820752-58711981-882B-4504-95F1-162117000128Q53305981-BD706546-2B2F-45B7-AD81-0E2F5FAC6A92
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bruce A Mueller
@nl
Bruce A Mueller
@sl
Bruce A. Mueller
@en
Bruce A. Mueller
@es
type
label
Bruce A Mueller
@nl
Bruce A Mueller
@sl
Bruce A. Mueller
@en
Bruce A. Mueller
@es
prefLabel
Bruce A Mueller
@nl
Bruce A Mueller
@sl
Bruce A. Mueller
@en
Bruce A. Mueller
@es
P106
P1153
7201392241
P21
P31
P496
0000-0002-1808-7904